难治性癫痫持续状态的管理:MORSE CODe国际队列研究对重症监护室患者的分析
该回顾性多中心队列研究纳入2015年1月至2018年12月四大洲9个中心的387次难治性癫痫持续状态发作,比较丙泊酚与咪达唑仑的疗效,发现两者功能结局相当,延长脑电图监测与连续静脉抗癫痫药物使用天数减少相关,但该关联在高收入国家尤为突出。
要点
- 丙泊酚与咪达唑仑治疗难治性癫痫持续状态的功能结局相当。
- 延长脑电图监测与连续静脉抗癫痫药物使用天数减少相关。
- 该关联在高收入国家和中高收入国家均可见,高收入国家尤为突出。
核心结论
- 在重症监护室使用丙泊酚或咪达唑仑治疗的难治性癫痫持续状态患者结局相当。
- 延长脑电图监测可能使医生安全地缩短麻醉药物输注时间,但这取决于难治性癫痫持续状态管理方案的实施。
- 包括脑电图目标在内的目标导向管理方法可能对难治性癫痫持续状态患者有前景。
研究设计与样本
- 回顾性识别2015年1月至2018年12月期间来自拉丁美洲中高收入经济体以及北美、欧洲和亚洲高收入经济体的9个中心中接受咪达唑仑或丙泊酚治疗的难治性癫痫持续状态患者。
- 共纳入387次难治性癫痫持续状态发作(386例患者),其中162次(42%)来自中高收入经济体,225次(58%)来自高收入经济体。
- 306例(79%)为急性病因,79例(21%)为远期病因。
- 初始难治性癫痫持续状态管理包括咪达唑仑266次(69%)和丙泊酚121次(31%)。
- 主要结局指标为出院时改良Rankin量表(mRS)评分0-2分定义为良好功能结局。
主要发现
- 初始接受咪达唑仑治疗的70次发作(26%)和初始接受丙泊酚治疗的42次发作(35%)需要加用第二种麻醉药物以治疗难治性癫痫持续状态。
- 接受咪达唑仑或丙泊酚治疗的患者基线特征和结局相似。
- 突破性发作(比值比[OR] 1.6,95%CI 1.3-2.0)和撤药性发作(OR 2.0,95%CI 1.7-2.5)与需要连续静脉抗癫痫药物(cIV-ACMs)治疗的天数增加相关。
- 延长脑电图监测与连续静脉抗癫痫药物使用天数减少相关(1-24小时 OR 0.5,95%CI 0.2-0.9;>24小时 OR 0.7,95%CI 0.5-1.0;参照脑电图<1小时)。
- 该关联在高收入国家和中高收入国家均可见,但在高收入国家尤为突出。
临床怎么用
- 作者认为,延长脑电图监测可能使医生安全地缩短麻醉药物输注时间,但这取决于难治性癫痫持续状态管理方案的实施。
- 作者认为,包括脑电图目标在内的目标导向管理方法可能对难治性癫痫持续状态患者有前景。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Status epilepticus that continues after the initial benzodiazepine and a second anticonvulsant medication is known as refractory status epilepticus (RSE). Management is highly variable because adequately powered clinical trials are missing. We aimed to determine whether propofol and midazolam were equally effective in controlling RSE in the intensive care unit, focusing on management in resource-limited settings. METHODS: Patients with RSE treated with midazolam or propofol between January 2015 and December 2018 were retrospectively identified among 9 centers across 4 continents from upper-middle-income economies in Latin America and high-income economies in North America, Europe, and Asia. Demographics, Status Epilepticus Severity Score, etiology, treatment details, and discharge modified Rankin Scale (mRS) were collected. The primary outcome measure was good functional outcome defined as a mRS score of 0-2 at hospital discharge. RESULTS: Three hundred eighty-seven episodes of RSE (386 patients) were included, with 162 (42%) from upper-middle-income and 225 (58%) from high-income economies. Three hundred six (79%) had acute and 79 (21%) remote etiologies. Initial RSE management included midazolam in 266 (69%) and propofol in 121 episodes (31%). Seventy episodes (26%) that were initially treated with midazolam and 42 (35%) with propofol required the addition of a second anesthetic to treat RSE. Baseline characteristics and outcomes of patients treated with midazolam or propofol were similar. Breakthrough (odds ratio [OR] 1.6, 95% CI 1.3-2.0) and withdrawal seizures (OR 2.0, 95% CI 1.7-2.5) were associated with an increased number of days requiring continuous intravenous anticonvulsant medications (cIV-ACMs). Prolonged EEG monitoring was associated with fewer days of cIV-ACMs (1-24 hours OR 0.5, 95% CI 0.2-0.9, and >24 hours OR 0.7, 95% CI 0.5-1.0; reference EEG <1 hour). This association was seen in both, high-income and upper-middle-income economies, but was particularly prominent in high-income countries. One hundred ten patients (28%) were dead, and 80 (21%) had good functional outcomes at hospital discharge. DISCUSSION: Outcomes of patients with RSE managed in the intensive care unit with propofol or midazolam infusions are comparable. Prolonged EEG monitoring may allow physicians to decrease the duration of anesthetic infusions safely, but this will depend on the implementation of RSE management protocols. Goal-directed management approaches including EEG targets may hold promise for patients with RSE. CLASSIFICATION OF EVIDENCE: This study provides Class III data that propofol and midazolam are equivalently efficacious for RSE.
引用
- Chiu WT, Campozano V, Schiefecker A, et al. Management of Refractory Status Epilepticus: An International Cohort Study (MORSE CODe) Analysis of Patients Managed in the ICU. Neurology. 2022. PMID: 35918156. doi:10.1212/WNL.0000000000200818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。